由光响应性多电解质-表面活性剂复合体驱动的接口向药物释放
Ipsita Pani1, Christina Spruck2, Michael Hardt1
1Institute of Physical Chemistry, University of Münster, Corrensstraße 28-30, 48149 Münster, Germany, Center for Soft Nanoscience (SoN), University of Münster, Busso-Peus-Straße 10, 48149 Münster, Germany.
Journal of colloid and interface science
|September 28, 2025
概括
聚-l-氨酸 (PLL) 增强光诱导的药物释放从阿里拉佐皮拉 (AAP) 纳米载体. 最佳的PLL度提高了多克索鲁比辛 (Dox) 释放到接口的水平,超过了单独的AAP小粒的水平.
科学领域:
- 材料科学 材料科学 材料科学
- 生物技术是生物技术.
- 化学工程是化学工程的重要组成部分.
背景情况:
- 光响应表面活性剂可以控制药物释放.
- 水性-疏水性接口是药物输送的相关模型.
- 多电解质可以改变纳米载体的特性.
研究的目的:
- 为了研究聚-l-氨酸 (PLL) 对阿里拉佐皮拉 (AAP) 纳米载体药物释放的影响.
- 为了优化PLL度,增强多克索鲁比 (Dox) 释放到接口.
- 了解PLL介导药物释放增强的机制.
主要方法:
- 表面活性剂-多电解质复合物的形成 (PLL/AAP).
- 电泳运动性和复合物的尺寸测量.
- 接口的振动总频生成 (SFG) 谱学.
主要成果:
- PLL/AAP复合体显示可调整的净电荷和合体稳定性.
- 最佳的PLL度 (比率为0.5) 显著提高了Dox释放到接口.
- 与单独的AAP菌根相比,Dox释放到接口的速度加速了大约6倍.
结论:
- PLL/AAP复合体提供了对光诱导药物释放的增强控制.
- 稳定的PLL/AAP复合物最大限度地减少了表面活性剂的竞争,改善了Dox吸附.
- 这种方法对向化疗输送系统有希望.
相关概念视频
Bioavailability Enhancement: Drug Permeability Enhancement
163
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
163
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
174
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
174


